Document Detail

Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents.
MedLine Citation:
PMID:  22876146     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Inhibitors of the vascular endothelial growth factor (vegf-is) signalling pathway have fundamentally changed the treatment of metastatic renal cell carcinoma (mrcc). Hypertension is one of the most common side effects of vegf-is and has been reported with almost every vegf-i used for treatment to date. The exact mechanism of vegf-i-induced hypertension appears complex and multifactorial, and it remains to be fully explained. No randomized clinical trials are available to guide the management of hypertension during vegf-i treatment in mrcc patients. The guiding principles suggested here summarize the consensus of opinions on the diagnosis and management of vegf-i-induced hypertension during treatment of mrcc obtained from an expert working group composed of 4 Canadian medical oncologists and 5 Canadian hypertension specialists. The Canadian Hypertension Education Program guidelines, available literature, and expert opinion were used to develop the guiding principles.
P Larochelle; C Kollmannsberger; R D Feldman; E L Schiffrin; L Poirier; F Patenaude; D Ruether; M Myers; G Bjarnason
Related Documents :
11510786 - Aerosolized pge1, pgi2 and nitroprusside protect against vascular leakage in lung ischa...
8793016 - Protective effect of nifedipine on myocardial stunning in isolated rabbit hearts: role ...
3184966 - Age-related changes in the ability of hypothermia and cardioplegia to protect ischemic ...
1877966 - Beneficial effects of bradykinin on porcine ischemic myocardium.
10622646 - Sevoflurane versus isoflurane in patients undergoing coronary artery bypass grafting: a...
6737056 - Experimental normal-pressure hydrocephalus is accompanied by increased transmantle pres...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current oncology (Toronto, Ont.)     Volume:  19     ISSN:  1198-0052     ISO Abbreviation:  Curr Oncol     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-08-09     Completed Date:  2012-08-27     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  9502503     Medline TA:  Curr Oncol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  202-8     Citation Subset:  -    
Institut de recherches cliniques de Montréal, Montreal, QC.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Outcomes of women with early-stage breast cancer receiving adjuvant trastuzumab.
Next Document:  Psychosocial care for cancer: a framework to guide practice, and actionable recommendations for Onta...